Median progression-free survivals (PFS) of patients treated with navelbin-cisplatin and paclitaxel-cisplatin were 4.5 months and 5 months, median overall survivals (OS) were 10.5 months and 10.8 months, respectively; the survivaldifference was not statistically significant (P>0.05).